Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer.
Implementation of a pathological diagnosis and treatment pathway may improve the molecular detection of lung cancer.
复制标题
病理诊断和治疗路径的实施可能会提高肺癌的分子检测水平
DOI：
10.21037/atm-21-6230
复制
发表时间：
2022-01
影响因子：
--
通讯作者：
Ma J
中科院分区：
文献类型：
--
作者：
Shi C;Wei B;Liu X;Meng L;Zhao C;Chang Y;Sun R;Zhang Z;Yu Y;Ma J
背景 美国病理学家学会 (CAP)、国际肺癌研究协会 (IASLC) 和分子病理学协会 (AMP) 的 2018 年指南制定了基准周转时间 (TAT)，根据该基准，肿瘤科医生应在 10 个工作日内获得结果。本文重点介绍了一种新的病理诊断和基因检测途径方案和样本采集器的应用过程。我们要解决临床上用于基因检测的穿刺样本不足、基因检测基准周转时间长的问题。方法在本研究中，我们建立并验证了一种新的病理诊断和治疗途径方案，并在中国河南省肿瘤医院进行了测试。 “生物收集器（BIOCO）”工具是我们团队设计的，采用聚氯乙烯（PVC）材料制成（专利申请号为201820902335.6）。它由收集器上的两个圆形磁铁组成，可以吸附在切片机刀架上，从而使其任意移动。它收集了修剪蜡块时丢弃的标本。我们分析了基于BIOCO的新协议的TAT、测试准确性和抗污染性，并与基于常规收集（ROUCO）的常规流程进行了比较。结果新途径采用传统病理学和分子病理学并行的方法，将TAT显着缩短至4-6天。使用BIOCO工具可以有效保存病理样本，避免交叉污染，减少重新采样带来的时间延迟。最重要的是，其准确性和有效性与传统收集方法一致。结论 基于BIOCO采集器的新型诊疗路径可作为医院病理科分子诊断平台的实用方法。
Background The 2018 Guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT), according to which the results should be available to the treating oncologist within 10 working days. This article focused on the application process of a new protocol for pathological diagnosis and gene testing pathway and a sample collector. We want to solve the problem that there are not enough puncture samples for gene testing, and the benchmark turnaround time of gene detection was long in clinic. Methods In this study, we established and validated a new protocol for a pathological diagnosis and treatment pathway that was tested in the Henan Cancer Hospital, China. The “Biology collector (BIOCO)” tool was designed by our team, was made of polyvinyl chloride (PVC) material (patent application number is 201820902335.6). It consisted of two round magnets on the collector that can be adsorbed on the microtome blade holder, thus making it to move arbitrarily. It collected specimens that were discarded when the wax block was trimmed. We analyzed the TAT, testing accuracy and anti-pollution of new protocol based on BIOCO, compared with the conventional process based on the Routine Collection (ROUCO). Results The new pathway adopts a parallel approach to conventional pathology and molecular pathology, which significantly shortens the TAT to 4–6 days. The use of the BIOCO tool can effectively save pathological samples, avoid cross-contamination, and reduce the time delay caused by re-sampling. Most importantly, its accuracy and effectiveness are consistent with conventional collection methods. Conclusions The new diagnosis and treatment pathway based on the BIOCO collector can be used as a practical approach for the molecular diagnostic platform of the hospital pathology department.